← Oncology Approval Tracker

FDA DECISION ·

Pebrilzo

pertuzumab-qcay · Biocon Biologics

Biosimilar approvalBiosimilarBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

A Perjeta biosimilar for specified HER2-positive breast cancer combinations: first-line metastatic use with trastuzumab and docetaxel; neoadjuvant use with trastuzumab and chemotherapy for locally advanced, inflammatory or early disease; and adjuvant use with trastuzumab and chemotherapy for early disease at high recurrence risk. The label sets the detailed eligibility limits.

SUPPORTING DATA

Evidence behind the decision

Study
FDA approved BLA 761501 under section 351(k), referencing US-licensed Perjeta.
Key result
The regulatory finding is biosimilarity for the labeled conditions of use.
Safety to report
The label includes boxed warnings for left ventricular dysfunction and embryo-fetal toxicity.
Evidence limits
This is not evidence of superior efficacy, a new indication for pertuzumab, or a demonstrated commercial launch.

LAMPGEN ANALYSIS

Why it matters

Biosimilarity expands product options for established regimens. The approval letter does not grant interchangeability.

What research teams should watch

For research sites, reconcile exact product identity, protocol-permitted substitutions, pharmacy accountability, infusion procedures and cardiac assessments before any switch.

PRIMARY RECORDS

Sources